MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » NeuroMetrix returns MLSC tax incentive funds

NeuroMetrix returns MLSC tax incentive funds

By

NURO logo

NeuroMetrix Inc. (NSDQ:NURO) and two other companies re-paid tax incentives to Massachusetts after failing to create enough jobs to meet the demands of the deal through which the funding came.

The Waltham, Mass.-based company, which has suffered sinking revenues over the past year, voluntarily surrendered the $300,000 that it procured through the Mass. Life Sciences Center’s $25 million Tax Incentive Program in late 2009, according to a center spokesman.

As part of the incentive program, NeuroMetrix committed to add 10 employees to its workforce by the close of 2010, but three consecutive quarters of decreasing sales, which were accompanied by a delisting warning from NASDAQ and major investor divestitures, made new hires unfeasible for the neurodiagnostics developer. In early January, the company laid off 27 percent of its workers, disbanded its sales operation and announced the planned phase out of its flagship product, the NC-stat.

Framingham, Mass.-based GTC Biotherapeutics Inc. also returned the $300,000 it received in 2009 through MLSC tax incentives for the creation of 10 jobs, according to the spokesman.

Genzyme Corp. (NSDQ:GENZ) returned the $6 million that the state provided the company to add 200 new jobs, according to MLSC. Although the it was able to meet those demands, two divestitures reduced its workforce significantly. The Cambridge, Mass.-based biotechnology firm sold off its diagnostics business to Sekisui Chemical Co. Ltd. (TYO:4204) for $265 million and offloaded the Genzyme Genetics unit to Laboratory Corporation of America Holdings (NYSE:LH) in a transaction valued at $925 million.

The MLSC won’t know whether all 28 companies that participated in the 2009 incentive program met its job creation requirements until Feb 1.

InfraReDx Inc., Interlace Medical, Inc., Lightlab Imaging Inc., Merrimack Pharmaceuticals, Nova Biomedical Corp., Organogenesis, Shire HGT Inc., Still Rivers Systems Inc. and Sunovion Inc. (formerly Sepracor Inc.) all made enough of an increase to their staffing numbers to have met the program’s demands, according to the spokesman. Each one of the companies won tax incentives in late 2010 as part of the MLSC’s $24 million round for 2011.

In case you missed it

RSS From Medical Design & Outsourcing

  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]
  • How Minnetronix Medical helped Lazurite with its wireless surgical camera
    Minnetronix Medical (St. Paul, Minnesota) has played an important development and manufacturing partner role with Lazurite’s wireless surgical camera system. It’s been nearly two months since Lazurite (formerly Indago) announced FDA 510(k) clearance of its ArthroFree system. ArthroFree combines proprietary low-heat, high-intensity Meridiem light engine technology with advanced camera, battery and wireless transmission technologies and… […]
  • Instron releases TrendTracker data analysis workflow platform
    Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze… […]
  • Henry Schein hires former Medline veteran to drive ‘One Distribution’ push
    Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor’s North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world’s largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company’s largest business group. The… […]
  • The road to a robot: Medtronic’s development process for its Hugo RAS system
    Elephants are the perfect analogy for surgical robotics, Medtronic (NYSE:MDT) VP of Marketing for Surgical Robotics Mike Stow says. Speaking on the “Road to a robot: Designing technology to address unmet needs & barriers” panel at DeviceTalks Boston last week, Stow explained that elephants are big, taking up a lot of space and that they eat a lot, making… […]
  • iRhythm stays silent on federal grand jury subpoenas
    More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a… […]
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
    A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented… […]
  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heatwave in Texas took at least six power plants offline Friday, with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no indication… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]

Leave a Reply